Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
Sanofi's annual report on its drug price increases echoed a theme heard during recent 2018 earnings calls, with list price hikes offset by rebates resulting in a net price decline.
You may also be interested in...
Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says
Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.
Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation
Here is what to expect from – and some free advice for – seven industry executives as they prepare for a hearing on drug pricing in the Senate Finance Committee.
Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.